A case of effective use of alemtuzumab in a male patient with T-cell lymphoma

Authors: Sokolov AN¹, Parovichnikova EN¹, Isaev VС¹, Ustinova ЕN¹, Shavlokhov VS¹, Atopkov VA¹, Model SV¹, Tsyba NN¹, Kaplanskaya IВ¹, Klyasova GA¹, Aleksanyan MZ.¹, Vishnevskaya ES¹, Togonidze DK¹, Mirzoyan EE¹, Savchenko VG¹
Affiliations:
Issue: Vol 79, No 12 (2004)
Pages: 73-75
Section: Editorial
URL: https://ter-arkhiv.ru/0040-3660/article/view/29971
ID: 29971

Cite item

Full Text

T-cell lymphoma, alemtuzumab, antibodies, CD52, recurrence, minimal residual disease, CD52

Hale G., Dyer M. J., Waldmann H. et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2 (8625): 1394-1399.
Dearden С. E., Matutes E., Catovsky D. Alemtuzumab in T-cell malignancies. Med. Oncol. 2002; 19 (suppl): S27-S32.
Dearden С. E., Dyer M. J., Catovsky D. et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98(6): 1721-1726.
Hainsworth J. D. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 2000; 5(5): 376-384.
Keating M. New drugs in hematologic malignancies. Haematologica 2001; 86(N 11, suppl.): 40-42.
Воробьев А. И., Виноградова Ю. Э. В кн. Воробьев А. И. (ред.) Руководство по гематологии. М.; 2003: 57-63, 113-131.
Воробьев А. И., Кременецкая А. М., Лорие Ю. Ю. "Старые" и "новые" опухоли лимфатической системы. Тер. арх. 2000; 7: 9-13.
Jaffe E. S., Harris N. L., Stein H., Wordiman J. W. Pathology and genetics of tumors and of haemopoietic and lymphoid tissues. WHO classifications of tumors. Lyon: IRCS Press; 2001.
Birhiray R. E., Shaw C., Brettman L. et al. Phenotypic transformation of CD52 (pos) to CD52 (neg) leukemic T-cell as a mechanism for resistance to CAMPATH-1H. Leukemia 2002; 16 (5): 861-864.

Supplementary Files

Action

1. JATS XML